Syncona reaps tenfold return from Blue Earth exit

Returns from the sale of Blue Earth Diagnostics for $450 million will allow majority shareholder Syncona to reinvest in its maturing portfolio companies as they scale, and will also drive new company launches, the firm's CEO Martin Murphy told BioCentury.

Bracco Imaging S.p.A. (Milan, Italy) is acquiring Blue Earth Diagnostics Ltd. (London, U.K.), a prostate cancer

Read the full 554 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE